David Alain Wohl, M.D.

David Alain Wohl, M.D., is a professor of medicine in the Division of Infectious Diseases at the University of North Carolina (UNC). He is site leader of the UNC AIDS Clinical Trials Unit at Chapel Hill, director of the North Carolina AIDS Education and Training Center (AETC), and co-director of HIV services for the North Carolina state prison system. In 2014, he became co-director of the UNC-Duke Clinical RM Ebola Response Consortium.

Dr. Wohl's research aims to optimize the treatment of HIV, including identifying the most effective therapeutic approaches and minimizing the adverse effects of therapy. He is also active in investigations focused on populations vulnerable to HIV, such as the incarcerated. He is active within the U.S. AIDS Clinical Trials Group and HIV Prevention Trials Network and served two terms as a member of the U.S. Department of Health and Human Services Antiretroviral Guidelines Panel.

As part of the response to the 2013-2016 Ebola outbreak in West Africa, Dr. Wohl led UNC clinical research efforts to test interventions for Ebola Virus Disease in Liberia and now directs a clinical cohort of Ebola survivors.

In addition to his research and administrative activities, Dr. Wohl maintains a large HIV continuity clinic at UNC.


Dr. Wohl has attended advisory boards for Abbott Laboratories, Tibotec, Janssen Pharmaceuticals, ViiV Healthcare, and Gilead Sciences. In addition, his university has received support for his research from Gilead Sciences and ViiV Healthcare. These disclosures were last updated on November 17, 2017.

Categories Covered:HIV Treatments in Development, PrEP (HIV Pre-Exposure Prophylaxis), Adverse Events, Comorbidities, and HIV, HIV Treatment Strategies, HIV Care and Services Outside the US, HIV Policy and Advocacy, Providing Quality HIV Care, First-Line HIV Treatment, Lamivudine (3TC, Epivir), Tenofovir Disoproxil Fumarate (Viread), HIV Care Continuum, HIV Epidemiology, HIV Case Management and Social Work, HIV Prevention Methods, Raltegravir (Isentress), Darunavir (Prezista), Ritonavir (Norvir), HIV Testing, Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (Complera), Atazanavir (Reyataz), Dolutegravir (Tivicay), Switching or Stopping HIV Treatment, Managing HIV Drug Resistance, HIV Education and Risk Management, HIV, Discrimination, and Law, Stavudine (d4T, Zerit), PEP (HIV Post-Exposure Prophylaxis), Managing Primary/Acute HIV Infection, U=U (Undetectable Equals Untransmittable, i.e. HIV Treatment as Prevention), Managing Long-Term HIV Survivors, Bictegravir/Emtricitabine/Tenofovir Alafenamide (Biktarvy, B/F/TAF)

Latest by David Alain Wohl, M.D.

GEMINI and the Rise of Two-Drug HIV Therapy: A Top HIV Clinical Development of 2018

The concept of a three-drug minimum for HIV therapy is rooted in a sequentialism that emerged with the dawning of antiretroviral treatment: one drug = nothing; two drugs = meh; three drugs = bingo! Over the years, in an effort to avoid peskier antire...

By David Alain Wohl, M.D.

Top 10 HIV Clinical Developments of 2018

Ten major events this year changed the way we think about HIV prevention, care, and treatment. David A. Wohl, M.D., walks us through each momentous story.

By David Alain Wohl, M.D.

Debate Over Dolutegravir in Early Pregnancy: A Top HIV Clinical Development of 2018

In 2018, the same year we learned that a two-drug initial HIV treatment regimen featuring dolutegravir (Tivicay, DTG) was viable for many of our patients, we also got a much-less-welcome dolutegravir (Tivicay, DTG)-related surprise. Early in the year...

By David Alain Wohl, M.D.

Integrase Inhibitors and Weight Gain: A Top HIV Clinical Development of 2018

Integrase inhibitors have revolutionized HIV treatment, as a glance at HIV treatment guidelines over the past few years makes clear. And with good reason: They're well tolerated, have a high barrier to resistance, and are potent as all get out. But t...

By David Alain Wohl, M.D.

PrEP and the Decline in New HIV Diagnoses: A Top HIV Clinical Development of 2018

Fact #1: New diagnoses of HIV dropped by almost 20% from 2008 to 2015. Fact #2: Pre-exposure prophylaxis (PrEP) uptake increased dramatically during the same period.

Cause and effect or happy accident? A team from Emory University and the neighborin...

By David Alain Wohl, M.D.

On-Demand Prevention in France: A Top HIV Clinical Development of 2018

We know HIV pre-exposure prophylaxis (PrEP) works, but is daily dosing really necessary? For many, the dictum of a "pill a day keeps the HIV away" is just fine. Yet, some have a harder time taking medications daily.

A few years ago, the IPERGAY stud...

By David Alain Wohl, M.D.

Bictegravir Has Finally Arrived: A Top HIV Clinical Development of 2018

I had to double check that it really was earlier this year that bictegravir was U.S. Food and Drug Administration-approved. On Feb. 7, the approval of the fixed-dose formulation of bictegravir with tenofovir alafenamide fumarate and emtricitabine (Bi...

By David Alain Wohl, M.D.

African-American Men and HIV Treatment Outcomes: A Top HIV Clinical Development of 2018

The HIV pandemic, like the virus itself, is opportunistic and parasitic. AIDS is a disease of poverty, disruption, stigma, and chaos. Wherever the social fabric is torn, HIV enters and occupies. Wherever communities struggle, HIV thrives. Here in the...

By David Alain Wohl, M.D.

The Long-Acting Bandwagon: A Top HIV Clinical Development of 2018

Word is getting out that, barring some major setback, long-acting injectable HIV antiretrovirals will soon be coming our way. Patients have come to my clinic asking about it; others muse that they wish there were shots instead of pills, and are heart...

By David Alain Wohl, M.D.

Designing HIV-Resistant People: A Top HIV Clinical Development of 2018

As unsavory as probably it is to most of us, there's big news in the claim by He Jiankui, Ph.D., that he was able to use Crispr-Cas9 technology to alter the genes of twin girls so they were born with their CD4 cells not expressing the CCR5 co-recepto...

By David Alain Wohl, M.D.